Following its introduction into clinical practice, the Amplatzer duct occluder (ADO) has achieved a definite place in the armamentarium of the interventional cardiologist for the closure of moderate to large sized PDAs. The device combines ease of use, including retrievability and repositioning when required, and a high occlusion rate (>99% complete occlusion of PDA within 6 months of implant, with the majority of occlusions occurring within 24 hours of implant). Possible complications, such as device embolization, protrusion of the retention disc of the device into the aorta producing aortic obstruction, or obstruction of a branch pulmonary artery by the device are also uncommon and can be avoided by choosing the appropriate sized device (with the pulmonary end of the device being 2mm larger in diameter than the minimum measured ductal diameter), and paying scrupulous attention to technique of deployment. The device can be safely deployed in infants >3.5 kg, and can currently close PDAs of upto 11 to 12mm in minimum diameter. A brief description of the device, the technique of implantation, and the clinical results to date are provided.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232577 | PMC |
Publication Analysis
Top Keywords
Similar Publications
It was a rare case of a 52-year-old female with a slender PDA combined with PFO related to a transient ischemic attack that did not improve with aspirin and/or clopidogrel treatment. We closed the PDA using the ADO-II occluder and closed the PFO with the occluder, resulting in symptom resolution.
View Article and Find Full Text PDFThe DIMASHQ Procedure: AO Plug pseudoaneurys repair in cending aorta using uality intracardiac ecocardiography.
JACC Case Rep
January 2025
Department of Internal Medicine, Jordan University of Science and Technology, Ar-Ramtha, Jordan.
The transcatheter management of complex cardiovascular diseases has significantly evolved, offering less invasive alternatives to traditional surgical interventions. In this report we describe 2 cases of patients who developed ascending aortic pseudoaneurysms soon after coronary artery bypass grafting. With meticulous computed tomography angiography planning and with live intracardiac echography, these patients underwent successful transcatheter repair using a 6/4-mm Amplatzer Duct Occluder II (Abbott) vascular plug.
View Article and Find Full Text PDFRetrieval of patent ductus arteriosus device embolization using hybrid approach: a case report.
Egypt Heart J
December 2024
Department of Cardiology, ESIC Medical College and Super Speciality Hospital, Room no 107, 1 st floor, Sanath Nagar, Hyderabad, 500038, India.
Background: Patent ductus arteriosus (PDA) is a congenital heart defect that requires closure to prevent complications like heart failure and pulmonary hypertension. Catheter-based closure using devices such as the Amplatzer duct occluder is the preferred method due to its minimally invasive nature. However, device embolization is a rare but recognized complication, particularly in small children or high-flow PDAs.
View Article and Find Full Text PDFCase Report: 3D imaging-assisted minimally-invasive hybrid closure surgery of a complex coronary artery fistulas.
Front Cardiovasc Med
November 2024
Department of Cardiothoracic Surgery, Dalian Municipal Women and Children's Medical Center(Group), Dalian, China.
Coronary artery fistulas (CAFs) are rare congenital heart defects that are typically managed through interventional closure, traditional surgery, or minimally invasive hybrid closure surgery. However, treating CAFs with complex anatomy, such as tortuous vessels, presents a significant challenge, particularly in young children. We report the case of a 3.
View Article and Find Full Text PDFArticle Synopsis
- Transcatheter closure of paravalvular leaks (PVL) is a viable treatment for high-risk patients, yet limited research exists on its effectiveness using Amplatzer devices in Japanese patients with mitral PVL.
- A study involving 12 patients (average age 78) showed successful closure procedures were performed, with a reduction in PVL severity and no major complications reported within 30 days.
- One year later, an all-cause mortality rate of 16.7% was noted, with 25% of patients needing further intervention due to symptom recurrence, indicating the treatment's potential but also the need for monitoring.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!